Literature DB >> 23150171

A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse).

Yanxing Chen1, Zhihou Liang, Julie Blanchard, Chun-Ling Dai, Shenggang Sun, Moon H Lee, Inge Grundke-Iqbal, Khalid Iqbal, Fei Liu, Cheng-Xin Gong.   

Abstract

Alzheimer's disease (AD) can be divided into sporadic AD (SAD) and familial AD (FAD). Most AD cases are sporadic and result from multiple etiologic factors, including environmental, genetic, and metabolic factors, whereas FAD is caused by mutations in the presenilins or amyloid-β (Aβ) precursor protein (APP) genes. A commonly used animal model for AD is the 3xTg-AD transgenic mouse model, which harbors mutated presenilin 1, APP, and tau genes and thus represents a model of FAD. There is an unmet need in the field to characterize animal models representing different AD mechanisms, so that potential drugs for SAD can be evaluated preclinically in these animal models. A mouse model generated by intracerebroventricular (icv) administration of streptozocin (STZ), the icv-STZ mouse, shows many aspects of SAD. In this study, we compared the non-cognitive and cognitive behaviors as well as biochemical and immunohistochemical alterations between the icv-STZ mouse and the 3xTg-AD mouse. We found that both mouse models showed increased exploratory activity as well as impaired learning and spatial memory. Both models also demonstrated neuroinflammation, altered synaptic proteins and insulin/IGF-1 (insulin-like growth factor-1) signaling, and increased hyperphosphorylated tau in the brain. The most prominent brain abnormality in the icv-STZ mouse was neuroinflammation, and in the 3xTg-AD mouse it was elevation of hyperphosphorylated tau. These observations demonstrate the behavioral and neuropathological similarities and differences between the icv-STZ mouse and the 3xTg-AD mouse models and will help guide future studies using these two mouse models for the development of AD drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150171      PMCID: PMC3582864          DOI: 10.1007/s12035-012-8375-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  60 in total

Review 1.  Do synaptic markers provide a window on synaptic effectiveness in the aged hippocampus?

Authors:  C A Barnes
Journal:  Neurobiol Aging       Date:  1999 May-Jun       Impact factor: 4.673

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Hippocampal alterations in rats submitted to streptozotocin-induced dementia model are prevented by aminoguanidine.

Authors:  Letícia Rodrigues; Regina Biasibetti; Alessandra Swarowsky; Marina C Leite; André Quincozes-Santos; Jorge A Quilfeldt; Matilde Achaval; Carlos-Alberto Gonçalves
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

4.  Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type.

Authors:  Tauheed Ishrat; Kehkashan Parveen; Mohd Moshahid Khan; Gulrana Khuwaja; M Badruzzaman Khan; Seema Yousuf; Ajmal Ahmad; Pallavi Shrivastav; Fakhrul Islam
Journal:  Brain Res       Date:  2009-04-15       Impact factor: 3.252

5.  Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway.

Authors:  Melita Salkovic-Petrisic; Florian Tribl; Manuela Schmidt; Siegfried Hoyer; Peter Riederer
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

6.  S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer's type.

Authors:  Hayate Javed; Mohd Moshahid Khan; Andleeb Khan; Kumar Vaibhav; Ajmal Ahmad; Gulrana Khuwaja; Md Ejaz Ahmed; Syed Shadab Raza; Mohammad Ashafaq; Rizwana Tabassum; M Saeed Siddiqui; O M El-Agnaf; Mohammed M Safhi; Fakhrul Islam
Journal:  Brain Res       Date:  2011-03-01       Impact factor: 3.252

7.  Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.

Authors:  Julie Blanchard; Lukas Wanka; Yunn-Chyn Tung; María del Carmen Cárdenas-Aguayo; Frank M LaFerla; Khalid Iqbal; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2010-08-10       Impact factor: 17.088

8.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

9.  Streptozocin- and alloxan-induced H2O2 generation and DNA fragmentation in pancreatic islets. H2O2 as mediator for DNA fragmentation.

Authors:  N Takasu; I Komiya; T Asawa; Y Nagasawa; T Yamada
Journal:  Diabetes       Date:  1991-09       Impact factor: 9.461

10.  Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice.

Authors:  Michael A Mastrangelo; William J Bowers
Journal:  BMC Neurosci       Date:  2008-08-12       Impact factor: 3.288

View more
  80 in total

1.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

Review 2.  Routes for the delivery of insulin to the central nervous system: A comparative review.

Authors:  Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Neurol       Date:  2018-11-27       Impact factor: 5.330

3.  Dysfunction of GABAergic neurons in the parafacial zone mediates sleep disturbances in a streptozotocin-induced rat model of sporadic Alzheimer's disease.

Authors:  Jin-Zhi Song; Su-Ying Cui; Xiang-Yu Cui; Xiao Hu; Yu-Nu Ma; Hui Ding; Hui Ye; Yong-He Zhang
Journal:  Metab Brain Dis       Date:  2017-10-28       Impact factor: 3.584

4.  Captopril and Valsartan May Improve Cognitive Function Through Potentiation of the Brain Antioxidant Defense System and Attenuation of Oxidative/Nitrosative Damage in STZ-Induced Dementia in Rat.

Authors:  Yasaman Arjmand Abbassi; Mohammad Taghi Mohammadi; Mahsa Sarami Foroshani; Javad Raouf Sarshoori
Journal:  Adv Pharm Bull       Date:  2016-12-22

5.  The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats.

Authors:  Simin Afshar; Siamak Shahidi; Ali Haeri Rohani; Alireza Komaki; Sara Soleimani Asl
Journal:  Psychopharmacology (Berl)       Date:  2018-07-19       Impact factor: 4.530

6.  Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.

Authors:  Yang Yu; Xiaojing Li; Julie Blanchard; Yi Li; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  J Neural Transm (Vienna)       Date:  2014-08-13       Impact factor: 3.575

7.  Decrease in Adult Neurogenesis and Neuroinflammation Are Involved in Spatial Memory Impairment in the Streptozotocin-Induced Model of Sporadic Alzheimer's Disease in Rats.

Authors:  Taysa Bervian Bassani; Jéssica M Bonato; Meira M F Machado; Valentín Cóppola-Segovia; Eric L R Moura; Silvio M Zanata; Rúbia M M W Oliveira; Maria A B F Vital
Journal:  Mol Neurobiol       Date:  2017-06-16       Impact factor: 5.590

8.  Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer's Rat Model.

Authors:  Yanxing Chen; Zhangyu Guo; Yan-Fang Mao; Tingting Zheng; Baorong Zhang
Journal:  Neurotox Res       Date:  2017-09-19       Impact factor: 3.911

Review 9.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 10.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.